Earlier this week, contract development and manufacturing organization (CDMO) Neuland Laboratories announced that it will open its peptide facility in summer 2026. The site, which will produce glucagon-like peptide-1 (GLP-1s), is just 40 miles from Hyderabad, India, in the town of Bonthapally.

“The site has been designed for ongoing expansion, with space to accommodate additional SPPS [solid phase peptide synthesis] synthesizers and multiple LPPS [liquid phase peptide synthesis] reactors as future modules come online,” vice chairman of Neuland Laboratories Saharsh Davuluri said in a public statement. “This allows us to scale responsibly and in line with customer needs.”

According to the release , the facility has already secured over $30 million in client commitments for the site, including the manufacturing of GLP-1s. The facility will span five of the site’s 17 acres, with four fully automated modular units fully modulated automated units able to produce over 100 kg annually.

“This new facility marks our strategic entry into commercial-scale peptidemanufacturing,” Davuluri said. “A key part of our strategy will be to first support innovator and emerging biotech companies across all areas of novel peptide development, as well as the ongoing demand for GLP-1 manufacturing.”

“We are now scaling rapidly and expect to roll out all modules of the new peptide facility in line with customer demand.”

Neuland has also been recruiting additional manufacturing staff for the site, accompanying its over one-million-liter active pharmaceutical ingredient (API) across its three current US Food and Drug Administration (FDA)-approved facilities. The company’s expanding reactors are also taking center stage, including reactors up to 3,000 liters for LPPS, and up to 6,000 liters for SPPS.

Neuland’s investment reflects an area of development that is experiencing significant growth. The exponential demand for GLP-1s has forced discussion on making peptide synthesis more sustainable. GLP-1s require over 45 times as much solvent for SPPS in comparison to the manufacturing of other therapies and are linked to so-called “forever chemicals” that have environmental and health consequences.

GLP-1 demand has also led to investments from CDMOs in building manufacturing capacity. Last year, Sai Life Sciences announced plans to build a peptide research and development facility in Hyderabad. Meanwhile, regulators and nonprofits have raced to ensure that production efforts are closely monitored to ensure GLP-1s are safe and pure.

Neuland’s Bonthapally site, which began construction in September 2025, has seven production blocks. It is part of a three-unit production line, including sites in Pashamylaram and Gaddapotharam. Neuland has already been engaged with by LIR Life Sciences to develop a transdermal GLP-1 platform, according to the European Pharmaceutical Review.

Quotes have been lightly edited for clarity and brevity.

Aug 13, 2026 TO Aug 14, 2026

The premier conference for advancing bioprocessing science into scalable, cost-efficient solutions for biosimilar, vaccine, and biologics production, designed to meet the needs of India’s dynamic ecosystem.